Annabel Samimy
Stock Analyst at Stifel
(3.47)
# 928
Out of 4,983 analysts
48
Total ratings
43.75%
Success rate
33.87%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Annabel Samimy
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PVLA Palvella Therapeutics | Initiates: Buy | $45 | $54.51 | -17.45% | 1 | Mar 26, 2025 | |
| GPCR Structure Therapeutics | Initiates: Buy | $50 | $21.79 | +129.46% | 1 | Jan 8, 2025 | |
| ALT Altimmune | Initiates: Buy | $18 | $3.63 | +395.87% | 1 | Jan 8, 2025 | |
| IVA Inventiva | Maintains: Buy | $20 → $17 | $5.32 | +219.55% | 4 | Nov 22, 2024 | |
| MBX MBX Biosciences | Initiates: Buy | $40 | $9.75 | +310.47% | 1 | Oct 8, 2024 | |
| KMDA Kamada | Initiates: Buy | $18 | $7.03 | +156.05% | 1 | Jul 3, 2024 | |
| PHAT Phathom Pharmaceuticals | Initiates: Buy | $24 | $10.98 | +118.58% | 1 | May 3, 2024 | |
| RGNX REGENXBIO | Maintains: Buy | $40 | $9.26 | +331.97% | 2 | Apr 12, 2024 | |
| VKTX Viking Therapeutics | Reiterates: Buy | $80 | $23.69 | +237.70% | 6 | Mar 15, 2024 | |
| JAZZ Jazz Pharmaceuticals | Maintains: Buy | $225 → $230 | $126.54 | +81.76% | 8 | Mar 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $23 → $25 | $6.52 | +283.44% | 1 | Mar 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $35 | $17.66 | +98.19% | 1 | Oct 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $60 → $65 | $23.82 | +172.88% | 3 | Aug 29, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $700 → $275 | $11.51 | +2,289.23% | 4 | Jun 26, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $45 | $37.42 | +20.26% | 1 | Mar 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $120 | $3.57 | +3,261.34% | 1 | Nov 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $24 | $0.50 | +4,709.62% | 1 | Aug 24, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $700 → $750 | $1.08 | +69,344.44% | 3 | Apr 16, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $25 → $24 | $43.99 | -45.44% | 7 | Apr 16, 2020 |
Palvella Therapeutics
Mar 26, 2025
Initiates: Buy
Price Target: $45
Current: $54.51
Upside: -17.45%
Structure Therapeutics
Jan 8, 2025
Initiates: Buy
Price Target: $50
Current: $21.79
Upside: +129.46%
Altimmune
Jan 8, 2025
Initiates: Buy
Price Target: $18
Current: $3.63
Upside: +395.87%
Inventiva
Nov 22, 2024
Maintains: Buy
Price Target: $20 → $17
Current: $5.32
Upside: +219.55%
MBX Biosciences
Oct 8, 2024
Initiates: Buy
Price Target: $40
Current: $9.75
Upside: +310.47%
Kamada
Jul 3, 2024
Initiates: Buy
Price Target: $18
Current: $7.03
Upside: +156.05%
Phathom Pharmaceuticals
May 3, 2024
Initiates: Buy
Price Target: $24
Current: $10.98
Upside: +118.58%
REGENXBIO
Apr 12, 2024
Maintains: Buy
Price Target: $40
Current: $9.26
Upside: +331.97%
Viking Therapeutics
Mar 15, 2024
Reiterates: Buy
Price Target: $80
Current: $23.69
Upside: +237.70%
Jazz Pharmaceuticals
Mar 15, 2024
Maintains: Buy
Price Target: $225 → $230
Current: $126.54
Upside: +81.76%
Mar 8, 2024
Reiterates: Buy
Price Target: $23 → $25
Current: $6.52
Upside: +283.44%
Oct 5, 2023
Initiates: Buy
Price Target: $35
Current: $17.66
Upside: +98.19%
Aug 29, 2023
Maintains: Buy
Price Target: $60 → $65
Current: $23.82
Upside: +172.88%
Jun 26, 2023
Downgrades: Hold
Price Target: $700 → $275
Current: $11.51
Upside: +2,289.23%
Mar 7, 2023
Initiates: Buy
Price Target: $45
Current: $37.42
Upside: +20.26%
Nov 10, 2022
Upgrades: Buy
Price Target: $120
Current: $3.57
Upside: +3,261.34%
Aug 24, 2021
Initiates: Buy
Price Target: $24
Current: $0.50
Upside: +4,709.62%
Apr 16, 2020
Maintains: Buy
Price Target: $700 → $750
Current: $1.08
Upside: +69,344.44%
Apr 16, 2020
Maintains: Hold
Price Target: $25 → $24
Current: $43.99
Upside: -45.44%